Sylvamo Corp
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
SLVM$39.38+19.1%Stored close · as of Nov 6, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-07.
0001856485-26-000034
Item 1A. Risk FactorsPurchases of Equity Securities by the Issuer and Affiliated PurchasersCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-06.
0001856485-26-000044
Item 1A. Risk FactorsPurchases of Equity Securities by the Issuer and Affiliated PurchasersThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 5 previous paragraphs and 9 current paragraphs.
2 unchanged; 3 reworded; 4 added; 0 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 1 previous and 1 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
The risk factors that affect our business and financial results are set forth under Part I, Item 1A, “Risk Factors,” in our 2025 Form 10-K. There have been no material changes to the risk factors described in the 2025 Form 10-K, except for the risk noted below. The risk factors in Item 1A. Risk Factors in the 2025 Form 10-K and the risks described in this Form 10-Q or our other SEC filings could cause our actual results to differ materially from those stated in any forward-looking statements.
Added paragraphs (4)
Current report
We may not complete the proposed sale of the Company’s Europe business.
Current report
On November 6, 2026, the Company announced that it had entered into a put option agreement with Midas Atlantic Partners, in partnership with The Najafi Companies, for a binding offer to acquire the Company’s Europe business. The Offer is for the business to be transferred to Midas Atlantic Partners with an agreed level of working capital and cash in exchange for the right to receive 20% of future distributions of the business. The Offer binds the buyer, but not the Company.
Current report
There is no assurance that the Offer will result in a sale of the Company’s Europe business. The Company’s ability to conduct the proposed sale depends on various factors, some beyond our control. The Company’s entry into a share purchase agreement (“SPA”), as proposed by the Option Agreement, is subject to the Company’s election to exercise the put option after certain conditions have been met, including our completion of required consultation processes with works councils and employee representatives in accordance with applicable law. We will complete these consultation processes before making any final decision on exercising the put option and entering into an SPA. Definitive SPA terms and completion of the transaction on a timely basis, if at all, would be subject to various factors and conditions, both known and unknown, including the satisfaction of conditions related to work councils’ approvals, the parties’ obtaining required regulatory approvals, and the satisfaction or waiver of other closing conditions.
Current report
Even if the Company were to complete the proposed sale, it might not have a positive effect on shareowner value and the Company might not realize the anticipated benefits of the transaction. The sale process and any resulting sale could have known and unknown adverse effects on the Company, including diverting management’s attention, disrupting our business, and exposing us to litigation. The Company has incurred, and will continue to incur, significant costs and expenses in connection with the proposed sale. Speculation and perceived uncertainties about developments related to the proposed sale could also cause volatility in the market price of the Company’s common stock.
Reworded paragraphs (3)
Previous wording
The risk factors that affect our business and financial results are set forth under Part I, Item 1A, “Risk Factors,” in our 2025 Form 10-K. There have been no material changes to the risk factors described in the 2025 Form 10-K. The risk factors in Item 1A. Risk Factors in the 2025 Form 10-K and the risks described in this Form 10-Q or our other SEC filings could cause our actual results to differ materially from those stated in any forward-looking statements.
Current wording
The risk factors that affect our business and financial results are set forth under Part I, Item 1A, “Risk Factors,” in our 2025 Form 10-K. There have been no material changes to the risk factors described in the 2025 Form 10-K, except for the risk noted below. The risk factors in Item 1A. Risk Factors in the 2025 Form 10-K and the risks described in this Form 10-Q or our other SEC filings could cause our actual results to differ materially from those stated in any forward-looking statements.
Previous wording
(a) 3,961 shares were acquired from employees from share withholdings under the Company’s long term incentive compensation program.
Current wording
(a) 4,800 shares were acquired from employees from share withholdings under the Company’s long term incentive compensation program.
Previous wording
On May 18, 2022, the Board approved a share repurchase program under which the Company may purchase up to an aggregate amount of $150 million of shares of its common stock (the “Repurchase Program”). In 2023 and again in the third quarter of 2025, the Board authorized an additional $150 million for the Repurchase Program, bringing the total program capacity to $450 million. As of June 30, 2026, $150 million remains available for repurchases. Pursuant to the Repurchase Program, the Company may repurchase in amounts, at prices and at such times as it deems appropriate, subject to market conditions and other considerations, including all applicable legal requirements. Repurchases may include purchases on the open market or privately negotiated transfers, under Rule 10b5-1 trading plans, under accelerated share repurchase programs, in tender offers and otherwise. The Repurchase Program does not obligate the Company to acquire any particular amount of shares of its common stock and may be modified or suspended at any time at the Company’s discretion. The Company did not repurchase any shares during the six months ended June 30, 2026.
Current wording
On May 18, 2022, the Board approved a share repurchase program under which the Company may purchase up to an aggregate amount of $150 million of shares of its common stock (the “Repurchase Program”). In 2023 and again in the third quarter of 2025, the Board authorized an additional $150 million for the Repurchase Program, bringing the total program capacity to $450 million. As of September 30, 2026, $150 million remains available for repurchases. Pursuant to the Repurchase Program, the Company may repurchase in amounts, at prices and at such times as it deems appropriate, subject to market conditions and other considerations, including all applicable legal requirements. Repurchases may include purchases on the open market or privately negotiated transfers, under Rule 10b5-1 trading plans, under accelerated share repurchase programs, in tender offers and otherwise. The Repurchase Program does not obligate the Company to acquire any particular amount of shares of its common stock and may be modified or suspended at any time at the Company’s discretion. The Company did not repurchase any shares during the nine months ended September 30, 2026.